Reimbursement
Transitional pass-through payment for devices in hospital outpatient care
Transitional pass-through payment for devices under OPPS: the 42 CFR 419.66 criteria, cost tests, the Breakthrough pathway and how long it lasts.
By the All In MedTech editorial team · Published November 19, 2026 · 7 min read
Transitional pass-through payment is a temporary extra Medicare payment for a new device category used in hospital outpatient care. Normally the cost of a device is bundled into the Ambulatory Payment Classification (APC) payment for the procedure. Pass-through status lets hospitals bill the device separately for at least two and up to three years, while cost data for the new device build up.
The program comes from section 1833(t)(6) of the Social Security Act and is set out for devices in 42 CFR 419.66. This post explains the eligibility rules, the three cost tests, the alternative pathway for Breakthrough devices, how payment is calculated and how the application process works.
Why pass-through exists
Under the outpatient prospective payment system (OPPS), each service is assigned to an APC with a set payment that is updated every year from hospital claims and cost reports. That system works for established technology. A new device that costs more than what it replaces is not reflected in the data until hospitals have used and billed it for a few years.
Pass-through bridges that gap. It is the outpatient counterpart of the inpatient new technology add-on payment, though the rules and calendar differ. For how both fit into device reimbursement as a whole, see how device reimbursement works.
Pass-through is granted to categories, not products
CMS does not give pass-through status to a single brand. It creates a device category, described by a HCPCS Level II code (usually a C-code), and any device that matches the category's long descriptor and CMS's guidance can be billed under it. Under 419.66(c)(1), a new category is only created if the device is not appropriately described by any existing or previously existing category, and was not being paid as an outpatient service as of December 31, 1996.
This means a second company with a similar device may be able to bill under a category another firm applied for, while that category is active.
Eligibility requirements for the device
Section 419.66(b) sets out what the device itself must be.
- FDA status. If FDA authorization is required, the device must have premarket approval or clearance, or be a Category B investigational device under an FDA investigational device exemption, or meet another FDA exemption.
- Newness. The application must be submitted within 3 years of the initial FDA approval or clearance. If there was a documented, verifiable delay in US market availability, the 3 years can run from market availability instead.
- Reasonable and necessary. The device must be reasonable and necessary for diagnosis or treatment, as section 1862(a)(1)(A) requires.
- Type of device. It must be an integral part of the service, used for one patient only, come into contact with human tissue, and be surgically implanted or inserted (permanently or temporarily) or applied in or on a wound or skin lesion.
- Not excluded. It cannot be capital equipment that hospitals depreciate, or a material or supply furnished incident to a service, such as a suture, customized surgical kit or clip (radiological site markers are an exception).
Substantial clinical improvement
Under 419.66(c)(2)(i), the device must show that it will substantially improve the diagnosis or treatment of an illness or injury, or the functioning of a malformed body part, compared with devices in earlier categories or other available treatments. CMS applies criteria similar to those it uses for inpatient add-on payments: for example, treating patients who have no other options, diagnosing a condition earlier, or improving outcomes such as fewer complications, fewer later interventions or faster recovery. CMS sets out its current reading of this test in the annual OPPS rule.
The cost significance tests
Unless the device is one of two exempt types (brachytherapy and temperature-monitored cryoablation devices that were already paid as outpatient services on August 1, 2000), its category must have a cost that is "not insignificant." Section 419.66(d) sets three tests, and the device must meet all of them.
| Test | What must be true | Plain meaning |
|---|---|---|
| 1 | Estimated average reasonable cost of the devices exceeds 25 percent of the applicable APC payment | The device is a large part of the procedure's payment |
| 2 | That cost exceeds the device-related portion of the APC payment by at least 25 percent | It costs much more than the devices already reflected in the APC |
| 3 | The difference between the device cost and the device portion of the APC exceeds 10 percent of the APC payment | The extra cost is large relative to the whole payment |
The device-related portion of an APC is often called the device offset. CMS publishes offset amounts for device-intensive APCs with each year's OPPS files, and these change every year.
The alternative pathway for Breakthrough devices
Under 419.66(c)(2)(ii), a device in FDA's Breakthrough Devices Program can qualify without showing substantial clinical improvement. The current regulation, as amended in August 2026, applies this pathway to devices whose pass-through status began on or after January 1, 2020, and on or before January 1, 2029, and requires that the device:
- received Breakthrough designation as of September 30, 2026; and
- received marketing authorization for the indication covered by that designation.
The device must still meet the eligibility requirements in 419.66(b) and the cost tests in 419.66(d). Because the dates in this pathway have changed through rulemaking, check the current text of the regulation and the latest OPPS final rule before planning around it.
How the payment is calculated
Under 419.66(h), the pass-through payment for a device is the hospital's charge for the device, adjusted to cost using the hospital's cost-to-charge ratio, minus the amount already included in the APC payment for the device. In other words, Medicare pays the hospital's estimated device cost above what the APC already covers.
Two points follow.
- If the APC already includes a large device offset, the separate pass-through amount is smaller.
- Total pass-through spending is subject to an overall statutory limit, and 419.62 allows CMS to reduce payments if projected spending would exceed it.
Pass-through devices used in ambulatory surgical centers are also paid separately there, under the ASC payment rules.
How long pass-through lasts
Section 419.66(g) limits pass-through to at least 2 years, but not more than 3 years, starting on the first date pass-through payment is made. CMS sets each category's end date through the annual OPPS rule, and ends categories at the close of a calendar quarter so that the total stays within the 2 to 3 year window. When status expires, the device cost is packaged back into the APC payment for the procedure, which by then should reflect the device's cost data.
The application process
Applications are submitted through CMS's online system, MEARIS, using the OPPS Device Pass-Through module. CMS's pass-through payment page links to the system and the application instructions.
CMS accepts applications on a rolling basis but reviews them quarterly. Its application instructions give the earliest possible effective date for a complete application submitted by the first business day of each quarter's deadline month:
| Complete application by first business day of | Earliest effective date |
|---|---|
| March | July 1 |
| June | October 1 |
| September | January 1 |
| December | April 1 |
Since calendar year 2016, every device application also goes through the annual OPPS rulemaking.
- An application approved in a quarterly review gets pass-through status from the start of the next quarter. CMS then confirms or ends that status in the next final rule.
- An application not approved quarterly is decided in the annual final rule, after it has been described in the proposed rule and opened to public comment.
Because CMS discusses each application in the proposed rule, information in an application, including cost data and study results, can become public. The OPPS proposed rule usually appears in the summer and the final rule around November, with changes effective January 1.
Pass-through, New Technology APCs and coverage
Pass-through applies to the device. For a new procedure with no cost history, CMS can instead assign a New Technology APC, which sets a payment band for the service itself until enough claims data exist. The two are separate applications, and a technology may need one, the other or neither.
Neither program decides coverage. A device with pass-through status is still subject to Medicare's reasonable and necessary standard, and any NCD or LCD that applies. See Medicare NCDs vs LCDs.
Finding current pass-through categories
CMS lists current and expired device categories, with their HCPCS codes and effective and expiration dates, on its OPPS pages and in the addenda to each OPPS rule. The annual final rule, published in the Federal Register, is the authoritative source for which categories are active in a given year. Because categories start and expire every quarter, always check the latest list rather than a saved copy.
Frequently asked questions
- What is transitional pass-through payment for devices?
- It is a temporary separate Medicare payment for a qualifying new device category used in hospital outpatient care, paid on top of the normal APC payment for the procedure.
- How long does device pass-through status last?
- Under 42 CFR 419.66(g), at least 2 years but not more than 3 years from the first date on which pass-through payment is made.
- What are the cost significance tests?
- The device's average cost must exceed 25 percent of the related APC payment, exceed the device portion of that APC by at least 25 percent, and the difference between the two must exceed 10 percent of the APC payment.
- Do Breakthrough devices qualify automatically?
- No. The alternative pathway removes the substantial clinical improvement test for qualifying Breakthrough devices, but the other eligibility and cost criteria still apply.
For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.